Study shows ITMTX may have beneficial role in progressive forms of MS
NEW YORK, June 28 /PRNewswire-USNewswire/ -- The Multiple Sclerosis Research Center of New York (MSRCNY), together with the International Multiple Sclerosis Management Practice (IMSMP), today announced that results from its Intrathecal Methotrexate Treatment in Multiple Sclerosis study have been published in this month's issue of Journal of Neurology. This study reports on the feasibility of using intrathecal methotrexate (ITMTX) in treatment unresponsive multiple sclerosis (MS) patients with progressive forms of the disease.
A retrospective, open-label, chart review analysis was conducted following patients with MS for up to eight treatments. Patients were considered for ITMTX treatment if they were unresponsive to or intolerant of FDA approved treatments. There was a one year follow-up after their eighth or last treatment. Patients underwent neurological assessments and expanded disability status scale (EDSS) evaluations. In 87 secondary progressive MS patients, EDSS scores were stable or improved in 89%, with significantly improved mean EDSS post-treatment compared to baseline. Of 34 primary progressive patients, EDSS scores were stable in 82%, with no significant progression in EDSS post-treatment compared to baseline. ITMTX may have a beneficial role in progressive forms of MS and is well tolerated with no serious adverse events.
"We have opened an avenue of treatment for an otherwise untreatable form of MS," said Dr. Saud A. Sadiq, Director of the IMSMP/MSRCNY and the study's lead author. "This is exciting news because it's the first time a treatment has been shown to be effective in the late stages/progressive forms of MS."
About Methotrexate
Methotrexate (MTX), an antimetabolite, has been in clinical use since 1948 when it was found to produce temporary remission of acute childhood leukemia. Because of its indirect immunosuppressive effects, MTX is used in treating autoimmune conditions such as rheumatoid arthritis and psoriasis.
About the IMSMP & MSRCNY
The International Multiple Sclerosis Management Practice and the Multiple Sclerosis Research Center of New York is a leader in MS healthcare and research. As a center of excellence, it establishes an unparalleled level of care for individualized, compassionate attention to patients' needs and well-being. Patients receive in-depth assessments and management plans with on-site physical therapists, social workers and neuropsychologists for cognitive rehabilitation. Appointments may be scheduled with a naturopathic physician, urologist/urogynecologist, pain specialist or massage therapist. The on-site infusion suite is open 7 days a week for intravenous medications, and a physician is accessible 24 hours a day/7 days a week. Patients benefit from the research lab by investigation into the cause of MS, disease mechanisms and treatment discoveries. As an international MS center, patients throughout the United States and from more than 30 countries on 5 continents rely on and visit the IMSMP for care.
Contact: Pamela Bloom, Media Relations, 646-557-3858
For Interest in Becoming a Patient: 212-265-8070
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Saud Sadiq, MD
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=93204
SOURCE International Multiple Sclerosis Management Practice
NEW YORK, June 28 /PRNewswire-USNewswire/ -- The Multiple Sclerosis Research Center of New York (MSRCNY), together with the International Multiple Sclerosis Management Practice (IMSMP), today announced that results from its Intrathecal Methotrexate Treatment in Multiple Sclerosis study have been published in this month's issue of Journal of Neurology. This study reports on the feasibility of using intrathecal methotrexate (ITMTX) in treatment unresponsive multiple sclerosis (MS) patients with progressive forms of the disease.
Advertisement
A retrospective, open-label, chart review analysis was conducted following patients with MS for up to eight treatments. Patients were considered for ITMTX treatment if they were unresponsive to or intolerant of FDA approved treatments. There was a one year follow-up after their eighth or last treatment. Patients underwent neurological assessments and expanded disability status scale (EDSS) evaluations. In 87 secondary progressive MS patients, EDSS scores were stable or improved in 89%, with significantly improved mean EDSS post-treatment compared to baseline. Of 34 primary progressive patients, EDSS scores were stable in 82%, with no significant progression in EDSS post-treatment compared to baseline. ITMTX may have a beneficial role in progressive forms of MS and is well tolerated with no serious adverse events.
Advertisement
"We have opened an avenue of treatment for an otherwise untreatable form of MS," said Dr. Saud A. Sadiq, Director of the IMSMP/MSRCNY and the study's lead author. "This is exciting news because it's the first time a treatment has been shown to be effective in the late stages/progressive forms of MS."
About Methotrexate
Methotrexate (MTX), an antimetabolite, has been in clinical use since 1948 when it was found to produce temporary remission of acute childhood leukemia. Because of its indirect immunosuppressive effects, MTX is used in treating autoimmune conditions such as rheumatoid arthritis and psoriasis.
About the IMSMP & MSRCNY
The International Multiple Sclerosis Management Practice and the Multiple Sclerosis Research Center of New York is a leader in MS healthcare and research. As a center of excellence, it establishes an unparalleled level of care for individualized, compassionate attention to patients' needs and well-being. Patients receive in-depth assessments and management plans with on-site physical therapists, social workers and neuropsychologists for cognitive rehabilitation. Appointments may be scheduled with a naturopathic physician, urologist/urogynecologist, pain specialist or massage therapist. The on-site infusion suite is open 7 days a week for intravenous medications, and a physician is accessible 24 hours a day/7 days a week. Patients benefit from the research lab by investigation into the cause of MS, disease mechanisms and treatment discoveries. As an international MS center, patients throughout the United States and from more than 30 countries on 5 continents rely on and visit the IMSMP for care.
Contact: Pamela Bloom, Media Relations, 646-557-3858
For Interest in Becoming a Patient: 212-265-8070
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Saud Sadiq, MD
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=93204
SOURCE International Multiple Sclerosis Management Practice
